Multipotent, permeable drug ASS234 inhibits Aβ aggregation, possesses antioxidant properties and protects from Aβ-induced apoptosis in vitro

Current Alzheimer Research

Volumn 10, Issue 8, 2013, Pages 797-808

  Bolea, Irene ^a   Gella, Alejandro ^b,c   Monjas, Leticia ^d   Pérez, Concepción ^d   Rodríguez Franco, María Isabel ^d   Marco Contelles, José ^e   Samadi, Abdelouahid ^e   Unzeta, Mercedes ^a  

^a INSTITUT DE NEUROCIÈNCIES   (Spain)

^b UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

^c Neurochemistry Working Group (SEQC)   (Spain)

^d INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^e INSTITUTO DE QUÍMICA ORGÁNICA GENERAL   (Spain)

Author keywords

Alzheimer's disease therapy; Amyloid ; Cholinesterase inhibitors; Multi target directed ligand; Neuroprotection; Propargylamine

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANTIOXIDANT; ASS 234; CATALASE; CENTRAL NERVOUS SYSTEM AGENTS; COPPER ZINC SUPEROXIDE DISMUTASE; DONEPEZIL; FA 65; UNCLASSIFIED DRUG; {N [5 (3 (1 BENZYLPIPERIDIN 4 YL)PROPOXY) 1 METHYL 1H INDOL 2 YL] N METHYLPROP 2 YN 1 AMINE};

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; BINDING SITE; BLOOD BRAIN BARRIER; CELL VIABILITY; CONTROLLED STUDY; DRUG INHIBITION; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; NEUROBLASTOMA CELL; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION;

ALZHEIMER DISEASE; ANTIOXIDANTS; APOPTOSIS; BLOOD-BRAIN BARRIER; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; HUMANS; INDOLES; NEURONS; PIPERIDINES;

EID: 84888071608     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/15672050113109990151     Document Type: Article

References (60)

1. Terry RD, Gonatas NK, Weiss M. Ultrastructural studies in Alzheimer's presenile dementia. Ann J Pathol 44: 269-297 (1964).
2. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder Ll. Abnormal phosphorylation of the microtubuleassociated protein pp(tau) in Alzheimer cystoskeletal pathology. Proc Natl Acad Sci USA 93: 4913-4917 (1986).
3. Coyle JT, Puttfarcken P. Oxidative stress, glutamate and neurodegenerative disorders. Science 262: 689-695 (1993).
4. Gella A, Bolea I. Oxidative Stress in Alzheimer's Disease: Pathogenesis, Biomarkers and Therapy. In Alzheimer's Disease Pathogenesis-Core Concepts, Shifting Paradigms and Therapeutic Targets, Suzanne De La Monte (Ed.), ISBN: 978-953-307-690-4, In-Tech. Available: http://www. intechopen. com/articles/show/title/oxidative-stress-in-alzheimer-s-disease-pathogenesis-biomarkersand-therapy (2011).
5. Huang X, Moir RD, Tanzi RE, Bush AI, Rogers JT. Redox-active metals, oxidative stress and Alzheimer's disease pathology. Ann NY Acad Sci 1012: 153-163 (2004).
6. Mishizen-Eberz AJ, Rissman RA, Carter TL, Ikonomovic MD, Wolfe BB, Armstrong DM. Biochemical and moleculat studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology. Neurobiol Dis 15: 80-92 (2004).
7. Dringerberg HC. Alzheimer's disease: more than ächolinergic disorder-evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia. Behav Brain Res 115: 235-249 (2000).
8. Francis PT, Sims NR, Procter AW, Bowen DM. Cortical pyramidal neuronal loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspective. J Neurochem 60: 1589-1604 (1993).
9. Buccafusco JJ, Terry AV Jr. Multiple central nervous system targets for eliciting beneficial effects on memory and cognition. J Pharmacol Exp Ther 295: 438-446 (2000).
10. Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, Melchiorre C. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 51: 347-372 (2008).
11. Galdeano C, Viayna E, Sola I, Formosa X, Camps P, Badia A, et al. Huprine-Tacrine Heterodimers as Anti-Amyloidogenic Compounds of Potential Interest Against Alzheimer's and Prion Diseases. J Med Chem 55: 661-669 (2012).
12. Marco-Contelles J, León R, de los Ríos C, Guglietta A, Terencio J, López MG, et al. Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease. J Med Chem 49: 7607-7610 (2006).
13. Zheng H, Youdim MBH, Fridkin M. Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neuroresto rative moieties for Alzheimer's therapy. J Med Chem 52: 4095-4098 (2009).
14. Zheng H, Gal S, Weiner LM, Bar-Am O, Waeshawsky A, et al. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 95: 68-78 (2005).
15. 2 muscarinic Receptor. J Med Chem 50: 5685-5695 (2007).
16. Sterling J, Herzig Y, Goren T. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J Med Chem 45: 5260-5279 (2002).
17. Samadi A, Chioua M, Bolea I, de los Ríos C, Iriepa I, Moraleda I, et al. Synthesis, biological assessment and molecular modelling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease. Eur J Med Chem 46: 4665-4668 (2011).
18. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356 (2002).
19. Teplow DB, Lazo ND, Bitan G, Bernstein T, Wyttenbach MT, Bowers MT, et al. Elucidating amyloid beta-protein folding and assembly: A multidisciplinary approach. Acc Chem Res 39: 635-645 (2006).
20. Bitan G, Fradinger EA, Spring SM, Teplow DB. Neurotoxic protein oligomers-what you see is not always what you get. Amyloid 12: 88-95 (2005).
21. Ladiwala ARA, Lin JC, Bale SS, Marcelino Cruz AM, Bhattacharya M, Dordick JS, et al. Resveratrol selectively remodels soluble oligomers and fibrils of amyloid ddinto off-pathway conformers. J Biol Chem 285: 24228-24237 (2010).
22. Cutillas B, Ambrosio S, Unzeta M. Neuroprotective effect of the monoamine oxidase inhibitor PF9601N on rat nigral neurons after 6-hydroxydopamine-striatal lesion. Neurosci Letters 329: 165-168 (2002).
23. Pérez V, Unzeta M. PF9601N, a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice. Neurochem Int 42: 221-239 (2003).
24. Pérez V, Romera M, Lizcano JM, Marco JL, Unzeta M. Protective effect PF9601N, a novel MAO-B inhibitor, on dopamine-lesioned PC12 cultured cells. J Pharm Pharmacol 55: 713-716 (2003).
25. Battaglia V, Sanz E, Salvi M, Unzeta M, Toninello A. Protective effect of PF9601N on mitochondrial permeability transition pore. Cell Mol Life Sci 63: 1440-1448 (2006).
26. +-treated SH-SY5Y human dopaminergic cells. J Neurochem 105: 2404-2417 (2008).
27. Sanz E, Quintana A, Hidalgo J, Marco JL, Unzeta M. PF9601N confers MAO-B independent neuroprotection in ER-stress-induced cell death. Mol Cell Neurosci 41: 19-31 (2009).
28. Samadi A, Marco-Contelles JL, Bolea I, Luque FJ, Unzeta M. New derivatives of propargylamine having neuroprotective capacity for the treatment of Alzheimer's and Parkinson's diseases. ES Patent 201030404, 2012.
29. Bolea I, Juárez-Jiménez J, de Los Ríos C, Chioua M, Pouplana R, Luque FJ, et al. Synthesis, biological evaluation and molecular modelling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. J Med Chem 54: 8251-8270 (2011).
30. Bartolini M, Bertucci C, Cavrini V, Andrisano V. Beta-amyloid aggregation induced by human acetylchonesterase: inhibition studies. Biochem Pharmacol 65: 407-416 (2003).
31. Ou B, Hampsch-Woodill M, Prior RL. Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe. J Agric Food Chem 49: 4619-4626 (2001).
32. Dávalos A, Gómez-Cordobés C, Bartolomé B. Extending applicability of the oxygen radical absorbance capacity (ORACfluorescein) assay. J Agric Food Chem 52: 48-54 (2004).
33. Di L, Kerns EH, Fan K, McConnell OJ, Carter GT. High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem 38: 223-232 (2003).
34. Rodríguez-Franco MI, Fernández-Bachiller MI, Pérez C, Hernández-Ledesma B, Bartolomé B. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J Med Chem 49: 459-462 (2006).
35. Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem 272: 22364-22372 (1997).
36. Harper DJ, Wong SS, Lieber CM, Lansbury PT. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol 4: 119-125 (1997).
37. Ono K, Condron MM, Teplow DB. Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci USA 106: 14745-14750 (2009).
38. 1-42 fibrillogenesis with atomic force microscopy. FASEB J 19: 1344-1346 (2005).
39. Jarret JT, Berger EP, Lansbury PT Jr. The C-terminus of beta protein is critical in amyloidogenesis. Ann N Y Acad Sci 695: 144-148 (1994).
40. Inestrosa NC, Alvarez A, Pérez CA, Moreno RD, Vicente M, Linker C, et al. Acetylcholinestearse accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme. Neuron 16: 881-891 (1996).
41. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44: 181-193 (2004).
42. Desagher S, Martinou JC. Mitochondria as the central control point of apoptosis. Trends Cell Biol 10: 369-377 (2000).
43. Wei W, Norton DD, Xiantao W, Kusiak JW. A[17-42 in Alzheimer's disease activates JNK and caspase-8 leading to neuronal apoptosis. Brain 125: 2036-2043 (2002).
44. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA, Yuan J. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403: 98-103 (2000).
45. Castellani R, Hirai K, Aliev G, Drew KL, Nunomura A, Takeda A, et al. Role of mitochondrial dysfunction in Alzheimer's disease. J Neurosci Res 70: 357-360 (2002).
46. Sofic E, Rimpapa Z, Kundurovic Z, Sapcanin A, Tahirovic I, Rustembegovic A, et al. Antioxidant capacity of the neurohormone melatonin. J Neural Transm 112: 349-358 (2005).
47. Quiroz-Baez R, Flores-Dominguez D, Arias C. Synaptic aging is associated with mitochondrial dysfunction, reduction antioxidant contents and increased vulnerability to amyloid-cctoxicity. Curr Alzheimer Res 10(3): 324-31 (2013).
48. Liu T, Bitan G. Modulating Self-Assembly of Amyloidogenic Proteins as a Therapeutic Approach for Neurodegenerative Diseases: Strategies and Mechanisms. ChemMedChem 7: 359-374 (2012).
49. Yang F, Lim GP, Begun AN, Ubeda OJ, Simmons MR, Ambegaokar SS, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280: 5892-5901 (2005).
50. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15: 558-566 (2008).
51. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. Amyloid-beta protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci USA 100: 330-335 (2003).
52. Bitan G, Vollers SS, Teplow D. Elucidation of primary structure elements controlling early amyloid-beta protein oligomerisation. J Biol Chem 278: 34882-34889 (2003).
53. Kamisnky YG, Marlatt MW, Smith MA, Kosenko EA. Subcellular and metabolic examination of amyloid beta peptides in Alzheimer disease pathogenesis: evidence for Abeta (25-35). Exp Neurol 221: 26-37 (2010).
54. Mark RJ, Lovel MA, Markesbery WR, Uchida K, Mattson MP. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J Neurochem 68: 255-264 (1997).
55. Youdim MBH, Weinstock M. Molecular basis of neuroprotective activities of rasagiline and the Anti-Alzheimer drug TV3326 [(Npropargyl-(3R)aminoindan-5-yl)-ethyl methyl carbamate]. Cell Mol Neurobiol 21: 555-573 (2001).
56. Bolea I, Gella A, Unzeta M. Propargylamine-derived multitargetdirected ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors. J Neural Transm 120(6): 893-902 (2013).
57. Mandel S, Weinreb O, Amit T, Youdim MB. Mechanisms of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev 48: 379-387 (2005).
58. Carrillo MC, Minami C, Kitani K, Mayurama W, Ohashi K, Yamamoto T, et al. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci 67: 577-585 (2000).
59. Pardridge WA. Alzheimer's disease drug development and the problem of the blood brain barrier. Alzheimer's Dementia 5: 427-432 (2009).
60. Stasiak A, Mussur M, Unzeta M, Samadi A, Marco-Contelles JL, Fogel WA. Effect of novel monoamine oxidases targeting compounds on brain neurotransmitters and behaviour in rat model of vascular dementia. Curr Pharm Des In Press (2012).